Belite Bio, Inc (NASDAQ:BLTE – Get Free Report) shares traded up 9.2% during mid-day trading on Thursday . The company traded as high as $66.12 and last traded at $66.12. 87,002 shares were traded during mid-day trading, an increase of 70% from the average session volume of 51,055 shares. The stock had previously closed at $60.55.
Analysts Set New Price Targets
A number of brokerages have commented on BLTE. Benchmark reaffirmed a “buy” rating and set a $57.00 target price on shares of Belite Bio in a research note on Tuesday, August 13th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of Belite Bio in a research report on Thursday, September 12th.
Read Our Latest Report on Belite Bio
Belite Bio Trading Up 10.5 %
Belite Bio (NASDAQ:BLTE – Get Free Report) last posted its quarterly earnings results on Friday, August 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.03). On average, equities research analysts predict that Belite Bio, Inc will post -1.19 EPS for the current year.
Hedge Funds Weigh In On Belite Bio
An institutional investor recently bought a new position in Belite Bio stock. Armistice Capital LLC bought a new stake in Belite Bio, Inc (NASDAQ:BLTE – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 148,000 shares of the company’s stock, valued at approximately $6,761,000. Armistice Capital LLC owned 0.50% of Belite Bio at the end of the most recent quarter. Hedge funds and other institutional investors own 0.53% of the company’s stock.
About Belite Bio
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.
See Also
- Five stocks we like better than Belite Bio
- Insider Trading – What You Need to Know
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- Earnings Per Share Calculator: How to Calculate EPS
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- The 3 Best Retail Stocks to Shop for in August
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.